• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene

    2/2/24 9:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBH alert in real time by email

    TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company ("Insight"), is voluntarily recalling two lots of TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid to the consumer level. A recent review by our manufacturer and their third-party lab found that samples from two lots of the product contained elevated levels of benzene. While benzene is not an ingredient in any Ting® Antifungal Spray products, the review showed that unexpected levels of benzene came from the propellant that sprays the product out of the can. Importantly, no other lots of TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid (either before or after these batch codes) and no other Ting® Antifungal Spray Liquid products are in the scope of this recall and may continue to be used by consumers safely and as intended.

    Risk Statement: Benzene is classified as a human carcinogen. Exposure to benzene can occur by inhalation, orally, and through the skin and it potentially can result in cancers including leukemia and blood cancer of the bone marrow and blood disorders which can be life threatening. Insight is recalling these products out of an abundance of caution. To date, the Company has not received any serious adverse events related to this recall. Benzene is ubiquitous in the environment. Humans around the world have daily exposures to it indoors and outdoors from multiple sources.

    TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid is packaged in blue and white aerosol cans with Lot codes located on the bottom of the can.

    TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid

    Samples of the recalled lots below have been found to contain elevated levels of Benzene related to the propellant that sprays the product out of the can. Benzene is not an ingredient in any Ting products.

    ProductNDCLot CodeExpirationPackage Size
    TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid63736-819-050H5054507/244.5 oz/128 g
    TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid63736-819-051G5064506/254.5 oz/128 g

    The affected TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid lots were distributed nationwide in the United States through a limited number of retailers and online.

    Insight has notified retailers via overnight mail to remove any remaining recalled product from shelves and follow the instructions provided in the Drug Recall Notification. The company will also offer reimbursement for consumers who have purchased TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid marked with one of the lot codes in the table above. Consumers can contact Insight Pharmaceuticals via e-mail at [email protected], through its website at https://www.prestigebrands.com/contact, or by phone at (800) 344-7239 on Monday – Friday 8:30-5:30 eastern time to receive a full refund by providing a picture of the bottom of the can of the TING® 1% Tolnaftate Athlete's Foot Spray Antifungal Spray Liquid with the affected lot number. Consumers that have product which is being recalled should stop using the product immediately and appropriately discard after taking the picture.

    No serious adverse events have been reported to date.

    Consumers with questions regarding this recall can contact Insight Pharmaceuticals via e-mail at [email protected], through its website at https://www.prestigebrands.com/contact, or by phone at (800) 344-7239 on Monday – Friday 8:30-5:30 eastern time. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this antifungal product.

    Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

    • Complete and submit the report Online: www.fda.gov/medwatch/report.htm
    • Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

    This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4e67b6ae-69a2-4b42-aee6-cff9f651a24a



    Investor Relations Contact
    Phil Terpolilli, CFA, 914-524-6819
    [email protected]

    Primary Logo

    Get the next $PBH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBH

    DatePrice TargetRatingAnalyst
    9/24/2025$80.00Neutral → Buy
    Sidoti
    12/9/2024$90.00Buy → Neutral
    Sidoti
    6/21/2024$65.00 → $93.00Neutral → Buy
    DA Davidson
    11/17/2022$71.00Buy
    Canaccord Genuity
    5/10/2022$65.00 → $70.00Hold → Buy
    Jefferies
    5/9/2022$63.00Perform → Outperform
    Oppenheimer
    3/11/2022$156.00 → $142.00Outperform
    BMO Capital
    11/15/2021$61.00 → $63.00Neutral
    DA Davidson
    More analyst ratings

    $PBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior VP Operations Zerillo Jeffrey sold $65,930 worth of shares (1,000 units at $65.93), decreasing direct ownership by 2% to 41,048 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    2/13/26 4:37:31 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Rosado Jose Luis was granted 3,426 shares, increasing direct ownership by 34,260% to 3,436 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    1/29/26 4:02:16 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Rosado Jose Luis claimed ownership of 10 shares (SEC Form 3)

    3 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    1/29/26 4:01:24 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prestige Consumer upgraded by Sidoti with a new price target

    Sidoti upgraded Prestige Consumer from Neutral to Buy and set a new price target of $80.00

    9/24/25 7:53:30 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer downgraded by Sidoti with a new price target

    Sidoti downgraded Prestige Consumer from Buy to Neutral and set a new price target of $90.00

    12/9/24 9:05:37 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer upgraded by DA Davidson with a new price target

    DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously

    6/21/24 7:05:28 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prestige Consumer Healthcare Announces Agreement to Acquire Breathe Right®, the Leader in Nasal Strips

    Entered agreement to acquire a portfolio of brands with revenue of $200 million and EBITDA of $95 millionBreathe Right is an iconic and category‑leading brand with strong margins and cash flow generationAcquisition reinforces Prestige's long-term organic growth algorithmTransaction expected to close in Prestige's first half fiscal 2027 TARRYTOWN, N.Y., March 20, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced that it has entered into a definitive agreement to acquire the Breathe Right® brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated ta

    3/20/26 6:15:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results

    Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025. "We exceeded our third quarter revenue outlook and delivered solid profitability in the quarter, which

    2/5/26 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference

    TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced it will issue its fiscal 2026 third quarter earnings release on Thursday, February 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.   To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recomme

    1/12/26 8:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

    SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/14/24 10:11:25 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

    SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/14/24 7:09:49 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Prestige Consumer Healthcare Inc. (Amendment)

    SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/13/24 5:12:15 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

    SCHEDULE 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    3/27/26 11:21:10 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

    3/20/26 6:15:25 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

    SCHEDULE 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/13/26 10:52:39 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Leadership Updates

    Live Leadership Updates

    View All

    Better For You Wellness Announces Results from Its February 5, 2022, Board of Directors Meeting

    Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic

    2/10/22 3:58:00 PM ET
    $LEAF
    $PBH
    $SPTN
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Financials

    Live finance-specific insights

    View All

    Prestige Consumer Healthcare Announces Agreement to Acquire Breathe Right®, the Leader in Nasal Strips

    Entered agreement to acquire a portfolio of brands with revenue of $200 million and EBITDA of $95 millionBreathe Right is an iconic and category‑leading brand with strong margins and cash flow generationAcquisition reinforces Prestige's long-term organic growth algorithmTransaction expected to close in Prestige's first half fiscal 2027 TARRYTOWN, N.Y., March 20, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced that it has entered into a definitive agreement to acquire the Breathe Right® brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated ta

    3/20/26 6:15:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results

    Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025. "We exceeded our third quarter revenue outlook and delivered solid profitability in the quarter, which

    2/5/26 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference

    TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced it will issue its fiscal 2026 third quarter earnings release on Thursday, February 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.   To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recomme

    1/12/26 8:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care